Follow
Outi M. H. Salo-Ahen
Outi M. H. Salo-Ahen
Adjunct Professor (Docent), Senior University Lecturer, Åbo Akademi University
Verified email at abo.fi
Title
Cited by
Cited by
Year
Computational approaches to identifying and characterizing protein binding sites for ligand design
S Henrich, OMH Salo‐Ahen, B Huang, FF Rippmann, G Cruciani, ...
Journal of Molecular Recognition: An Interdisciplinary Journal 23 (2), 209-219, 2010
2502010
Molecular dynamics simulations in drug discovery and pharmaceutical development
OMH Salo-Ahen, I Alanko, R Bhadane, AMJJ Bonvin, RV Honorato, ...
Processes 9 (1), 71, 2020
2232020
Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes
SM Saario, OMH Salo, T Nevalainen, A Poso, JT Laitinen, T Järvinen, ...
Chemistry & biology 12 (6), 649-656, 2005
1942005
Towards peptide vaccines against Zika virus: Immunoinformatics combined with molecular dynamics simulations to predict antigenic epitopes of Zika viral proteins
M Usman Mirza, S Rafique, A Ali, M Munir, N Ikram, A Manan, ...
Scientific reports 6 (1), 37313, 2016
1332016
Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro
MA Alamri, M Tahir Ul Qamar, MU Mirza, R Bhadane, SM Alqahtani, ...
Journal of Biomolecular Structure and Dynamics 39 (13), 4936-4948, 2021
1072021
Development of a 3D model for the human cannabinoid CB1 receptor
OMH Salo, M Lahtela-Kakkonen, J Gynther, T Järvinen, A Poso
Journal of medicinal chemistry 47 (12), 3048-3057, 2004
1042004
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase
D Cardinale, G Guaitoli, D Tondi, R Luciani, S Henrich, OMH Salo-Ahen, ...
Proceedings of the National Academy of Sciences 108 (34), E542-E549, 2011
1032011
Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands
KH Raitio, OMH Salo, T Nevalainen, A Poso, T Jarvinen
Current medicinal chemistry 12 (10), 1217-1237, 2005
872005
CB receptor ligands from plants
R Bauer, K Woelkart, OMH Salo-Ahen
Current Topics in Medicinal Chemistry 8 (3), 173-186, 2008
792008
Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor
OMH Salo, KH Raitio, JR Savinainen, T Nevalainen, M Lahtela-Kakkonen, ...
Journal of medicinal chemistry 48 (23), 7166-7171, 2005
762005
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system
SM Saario, A Poso, RO Juvonen, T Järvinen, OMH Salo-Ahen
Journal of medicinal chemistry 49 (15), 4650-4656, 2006
752006
Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs
D Garg, S Henrich, OMH Salo-Ahen, H Myllykallio, MP Costi, RC Wade
Journal of medicinal chemistry 53 (18), 6539-6549, 2010
592010
Identification of WIN55212‐3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor
JR Savinainen, T Kokkola, OMH Salo, A Poso, T Järvinen, JT Laitinen
British journal of pharmacology 145 (5), 636-645, 2005
582005
Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis
B Jabbar, S Rafique, OMH Salo-Ahen, A Ali, M Munir, M Idrees, MU Mirza, ...
Frontiers in Immunology (Viral Immunology) 9 (Article 3000), 10.3389/fimmu …, 2018
572018
Homodimeric enzymes as drug targets
D Cardinale, OMH Salo-Ahen, S Ferrari, G Ponterini, G Cruciani, ...
Current medicinal chemistry 17 (9), 826-846, 2010
542010
Dynamics of CYP51: implications for function and inhibitor design
X Yu, V Cojocaru, G Mustafa, OMH Salo‐Ahen, GI Lepesheva, RC Wade
Journal of Molecular Recognition 28 (2), 59-73, 2015
402015
Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems
C Sahlgren, A Meinander, H Zhang, F Cheng, M Preis, C Xu, TA Salminen, ...
Advanced healthcare materials, 2017
382017
Inhibition of oncogenic kinases: an in vitro validated computational approach identified potential multi-target anticancer compounds
N Ikram, MU Mirza, M Vanmeert, M Froeyen, OMH Salo-Ahen, M Tahir, ...
Biomolecules 9 (4), 124, 2019
312019
Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase
OMH Salo-Ahen, A Tochowicz, C Pozzi, D Cardinale, S Ferrari, Y Boum, ...
Journal of medicinal chemistry 58 (8), 3572-3581, 2015
312015
The functional role of cysteines adjacent to the NRY motif of the human MT1 melatonin receptor
T Kokkola, OMH Salo, A Poso, JT Laitinen
Journal of pineal research 39 (1), 1-11, 2005
282005
The system can't perform the operation now. Try again later.
Articles 1–20